Aeterna

questo vi può aiutare
Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "Although the data received for the open-label safety study Z-041 with a nearly 6 point reduction in IPSS are in line with what we had observed in our Phase 2 program, we are disappointed by the failure to achieve the primary endpoint in the efficacy study Z-033. We remain committed to the ongoing Phase 3 program with cetrorelix in BPH and are working towards receiving the results of the second pivotal efficacy study Z-036 in November."
http://finance.yahoo.com/news/AEterna-Zentaris-Announces-prnews-2589901731.html?x=0&.v=1
 
Bella
 

Allegati

  • AEZS.png
    AEZS.png
    23 KB · Visite: 274

Users who are viewing this thread

Back
Alto